Thrombin

Unlike most single-function cascade effectors, thrombin balances two opposing sets of activities to maintain circulatory homeostasis: it promotes clotting after vessel injury by activating platelets and generating fibrin mesh, but can also bind to the endothelial surface protein thrombomodulin to trigger anticoagulant pathways that prevent dangerous, unprovoked thrombosis inside intact blood vessels. This balanced regulatory role makes it one of the most tightly controlled enzymes in human circulatory biology.

Early bovine thrombin products used widely in 20th century surgery were found to trigger formation of cross-reactive antibodies that attacked native human coagulation factors, in some cases leading to life-threatening bleeding events. The successive development of human plasma-derived and then fully recombinant thrombin resolved most of these safety concerns, and modern thrombin products are often paired with absorbable gelatin sponges or fibrin glue components to improve hemostatic performance on bleeding sites that cannot be easily sutured or ligated.

Contemporary research has found thrombin also acts as a signaling molecule that modulates inflammatory responses, tissue repair, and even neuronal development outside of its core coagulation role. This opens new potential therapeutic directions beyond hemostasis, while it also remains the primary target for a class of widely used anticoagulant drugs including leech-derived hirudin and synthetic direct thrombin inhibitors that are used to prevent clotting during cardiac procedures and for thrombotic condition management.